Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

INCLUSION CRITERIA: * patient must have confirmed diagnosis of refractory or relapsed AML that expresses a FLT-3 mutation * patient must have life expectancy of more than 2 months * patient must be fully recovered from reversible side effects of previous therapy for cancer EXCLUSION CRITERIA: * total bilirubin, ALT or AST greater than 2 times upper limit of normal * patient \<65 years of age with estimated creatinine clearance less than 60 mL/min; patient \>65 years of age with serum creatinine \> 1.5 times the upper limit of normal (ULN) * received any investigational drug within past 4 weeks * GI disturbance/malabsorption that may affect absorption of CEP-701 * HIV positive * received NSAID within prior 14 days * has active infection